Stay updated on Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.

Latest updates to the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.5.4 was added and the previous revision v3.5.3 was removed, indicating a small metadata update to the page.SummaryDifference0.0%

- Check19 days agoChange DetectedA new bibliographic citation to a 2025 biomarker-driven study on metastatic gastric/GEJ cancer was added to Publications, expanding the referenced literature for the trial page.SummaryDifference0.0%

- Check33 days agoChange DetectedThe study locations are updated to reflect the renamed New Aquitaine region for Pessac and Poitiers, and the page revision is updated to v3.5.3.SummaryDifference0.1%

- Check55 days agoChange DetectedPadua, Italy was removed and Padova, Italy was added in the study locations.SummaryDifference0.2%

- Check69 days agoChange DetectedAdded a Publication entry for the study: 'First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial' with PubMed attribution, including the author list and Naples, Italy affiliation.SummaryDifference0.2%

- Check84 days agoChange DetectedThe page revision entry was updated from v3.4.2 to v3.4.3. The change adds Revision: v3.4.3 and removes Revision: v3.4.2.SummaryDifference0.0%

Stay in the know with updates to Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.